The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Expression of therapeutic proteins after delivery of chemically modified mRNA in mice
Abstract
Current viral vectors for gene therapy are associated with serious safety concerns, including leukemogenesis, and nonviral vectors are limited by low gene transfer efficiency. Here we investigate the therapeutic utility of chemically modified mRNA as an alternative to DNA-based gene therapy. A combination of nucleotide modifications abrogates mRNA interaction with Toll-like receptor (TLR)3, TLR7, TLR8 and retinoid-inducible gene I (RIG-I), resulting in low immunogenicity and higher stability in mice. A single intramuscular injection of modified murine erythropoietin mRNA raises the average hematocrit in mice from 51.5% to 64.2% after 28 days. In a mouse model of a lethal congenital lung disease caused by a lack of surfactant protein B (SP-B), twice weekly local application of an aerosol of modified SP-B mRNA to the lung restored 71% of the wild-type SP-B expression, and treated mice survived until the predetermined end of the study after 28 days.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Substitution of chemically modified nucleotides in messenger ribonucleic acid (mRNA) enhances stability and transfection capability, and decreases immunogenicity1–3”
From Complete substitution with modified nucleotides in self-amplifying RNA suppresses the interferon response and increases potency (2025) · cites this paper as [2]
In the citing paper
“Conclusive data have also been presented for mRNA as a platform for protein (replacement) therapies (Kormann et al, 2011; Kariko et al, 2012; Zangi et al, 2013; Thess et al, 2015; Balmayor et al, 2016).”
From mRNA mediates passive vaccination against infectious agents, toxins, and tumors (2017) · cites this paper as Kormann et al, 2011
In the citing paper
“Whereas unmodified Epo mRNA was immunostimulatory and failed to induce sufficient protein expression in mice, a few micrograms of nucleoside-modified mRNA were enough to achieve detectable protein expression and physiological effects upon direct administration to murine muscle.”
From Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals (2015) · cites this paper as [26]
In the citing paper
“Our work principally confirms that conventional unmodified mRNAs are inferior to molecules harboring specific nucleoside modifications as suggested by various recent reports,23,24,25,26,27 however, the picture changes dramatically with a sophisticated sequence-engineering.”
From Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals (2015) · cites this paper as [26]
In the citing paper
“Two independent studies on erythropoietin-encoding mRNA found a superiority of nucleoside-modified compared to unmodified mRNA.”
From Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals (2015) · cites this paper as [26]
In the citing paper
“While local administrations may be possible without the need for an mRNA delivery system,26,42”
From Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals (2015) · cites this paper as [26]
In the citing paper
“Kormann et al., demonstrated that 2 weeks following injection of nucleoside-modified mRNA containing 25% thio-uridine and 25% 5-methylcytidine resulted in Epo levels five times greater than that in untreated animals.”
From Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency (2022) · cites this paper as Kormann et al. 2011
In the citing paper
“Unmodified mRNA, on the other hand, showed no significant alterations and merely elicited a considerable immunological response (Kormann et al. 2011).”
From Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency (2022) · cites this paper as Kormann et al. 2011
In the citing paper
“In another study by Kormann and colleagues, translation was maximized and innate immune response was reduced in a mouse lung disease model by introducing chemically-modified nucleotides during in vitro transcription of mRNA (IVT-mRNA), coding for surfactant protein B (SP-B) with a 25% replacement of cytidine and uridine by modified 5-methyl cytidine (5-methyl CTP) and 2-thio uridine (2-thio UTP),”
From Human cellular CYBA UTR sequences increase mRNA translation without affecting the half-life of recombinant RNA transcripts (2016) · cites this paper as [19]
In the citing paper
“Therefore, chemists have creatively modified nucleic acid bases, sugar rings, 3 ‘and 5’ ends. These modifications are resistant to nuclease degradation, reduce immunogenicity and improve the interaction with target cells.311”
From Smart nanoparticles for cancer therapy (2023) · cites this paper as [311]
In the citing paper
“Studies have shown that when poly(A) tail size increases to 120 bp, the expression level of the corresponding protein increases accordingly. However, when poly(A) tail size is greater than 120 bp, the expression level of the corresponding protein did not increase.152”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [152]
In the citing paper
“Kormann and colleagues152 replaced 25% of mRNA cytosine with m5C and 25% of uridine with s2U, which improved mRNA stability and increased protein translation in mice.”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [152]
In the citing paper
“In contrast, no significant changes were detected with unmodified mRNA, which only evoked a substantial immune activation [44].”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [44]
In the citing paper
“In a therapeutic setting, Kormann et al., demonstrated that nucleoside-modified mRNA encoding erythropoietin (Epo), in which 25% thio-uridine and 25% 5-methylcytidine was incorporated, resulted in five times higher Epo levels compared to untreated mice, two weeks after i.m. administration.”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [44]
Citations
Cites
Pfaffl, M. W. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.9.e36 · Cited by 7,377
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Warren, L., Manos, P. D., Ahfeldt, T., Loh, Y.-H., Li, H., Lau, F., Ebina, W., Mandal, P. K., Smith, Z. D., Meissner, A., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.08.012 · Cited by 2,662
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Efficacy of Gene Therapy for X-Linked Severe Combined Immunodeficiency
Hacein‐Bey‐Abina, S., Hauer, J., Lim, A., Pïcard, C., Wang, G. P., Berry, C. C., Martinache, C., Rieux‐Laucat, F., Latour, S., Belohradsky, B. H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000164 · Cited by 654
Deficiency of Pulmonary Surfactant Protein B in Congenital Alveolar Proteinosis
Nogee, L. M., deMello, D. E., Dehner, L. P., & Colten, H. R. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302113280606 · Cited by 627
Holtkamp, S., Kreiter, S., Selmi, A., Simon, P., Koslowski, M., Huber, C., Türeci, O., & Sahin, U. (2006) · Blood · doi:10.1182/blood-2006-04-015024 · Cited by 625
Hydrophobic Surfactant Proteins in Lung Function and Disease
Whitsett, J. A., & Weaver, T. E. (2002) · New England Journal of Medicine · doi:10.1056/nejmra022387 · Cited by 519
A randomized controlled study of iron supplementation in patients treated with erythropoietin
Macdougall, I. C., Tucker, B., Thompson, J., Tomson, C., Baker, L. R. I., & Raine, A. E. G. (1996) · Kidney International · doi:10.1038/ki.1996.487 · Cited by 415
Targeted delivery of magnetic aerosol droplets to the lung
Dames, P., Gleich, B., Flemmer, A. W., Hajek, K., Seidl, N., Wiekhorst, F., Eberbeck, D., Bittmann, I., Bergemann, C., Weyh, T., et al. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.217 · Cited by 382
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 731
Conway, A., Mendel, M., Kim, K., McGovern, K., Boyko, A., Zhang, L., Miller, J. C., DeKelver, R. C., Paschon, D. E., Mui, B. L., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.03.003 · Cited by 95
“Activation of the innate anti-viral response has been commonly observed after administration of in vitro transcribed mRNAs, likely due to activation of pattern recognition receptors(31) and incorporation of modified nucleosides, particularly uridine analogs (Figure 2A) improved the activity of mRNAs both in cultured c…”
BackgroundLi, X., Qi, J., Wang, J., Hu, W., Zhou, W., Wang, Y., & Li, T. (2024) · Theranostics · doi:10.7150/thno.84291 · Cited by 100
Photocaged 5′ cap analogues for optical control of mRNA translation in cells
Klöcker, N., Weissenboeck, F. P., van Dülmen, M., Špaček, P., Hüwel, S., & Rentmeister, A. (2022) · Nature Chemistry · doi:10.1038/s41557-022-00972-7 · Cited by 93
Xiong, H., Liu, S., Wei, T., Cheng, Q., & Siegwart, D. J. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.06.030 · Cited by 92
Laird, N. Z., Acri, T. M., Tingle, K., & Salem, A. K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.009 · Cited by 93
Lou, B., Koker, S. D., Lau, C. Y. J., Hennink, W. E., & Mastrobattista, E. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00524 · Cited by 92
Biomaterials as vectors for the delivery of CRISPR–Cas9
Eoh, J. H., & Gu, L. (2019) · Biomaterials Science · doi:10.1039/c8bm01310a · Cited by 92
Uchida, S., & Kataoka, K. (2019) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.36614 · Cited by 90
mRNA: A Novel Avenue to Antibody Therapy?
Schlake, T., Thran, M., Fiedler, K., Heidenreich, R., Petsch, B., & Fotin‐Mleczek, M. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.03.002 · Cited by 93
Synthetic modified messenger RNA for therapeutic applications
Gao, M., Zhang, Q., Feng, X.-H., & Liu, J. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.06.020 · Cited by 89
Golombek, S., Pilz, M., Steinle, H., Kochba, E., Levin, Y., Lunter, D., Schlensak, C., Wendel, H. P., & Avci-Adali, M. (2018) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2018.03.005 · Cited by 88
Lazzaro, S., Giovani, C., Mangiavacchi, S., Magini, D., Maione, D., Baudner, B. C., Geall, A. J., Gregorio, E. D., D’Oro, U., & Buonsanti, C. (2015) · Immunology · doi:10.1111/imm.12505 · Cited by 89
Liu, Z., Zhou, W. Y., Cheng, Q., & Kong, T. (2020) · Advanced Materials · doi:10.1002/adma.202002932 · Cited by 90
Screening of mRNA Chemical Modification to Maximize Protein Expression with Reduced Immunogenicity
Uchida, S., Kataoka, K., & Itaka, K. (2015) · Pharmaceutics · doi:10.3390/pharmaceutics7030137 · Cited by 90
McGee, J. E., Kirsch, J. R., Kenney, D., Cerbo, F., Chavez, E. C., Shih, T.-Y., Douam, F., Wong, W. W., & Grinstaff, M. W. (2025) · Nature Biotechnology · doi:10.1038/s41587-024-02306-z · Cited by 87
Cell-Penetrating Peptides: Emerging Tools for mRNA Delivery
Yokoo, H., Oba, M., & Uchida, S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics14010078 · Cited by 88
Spleen-Targeted mRNA Vaccine Doped with Manganese Adjuvant for Robust Anticancer Immunity In Vivo
Luo, Z., Lin, Y., Meng, Y., Li, M., Ren, H., Shi, H., Cheng, Q., & Wei, T. (2024) · ACS Nano · doi:10.1021/acsnano.4c09902 · Cited by 88
A new developing class of gene delivery: messenger RNA-based therapeutics
Zhao, M., Ahern, J. O., Lyu, J., Pierucci, L., Zhou, D., & Wang, W. (2017) · Biomaterials Science · doi:10.1039/c7bm00712d · Cited by 95
A lung tropic AAV vector improves survival in a mouse model of surfactant B deficiency
Kang, M. H., van Lieshout, L. P., Xu, L., Domm, J. M., Vadivel, A., Renesme, L., Mühlfeld, C., Hurskainen, M., Mižíková, I., Pei, Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17577-8 · Cited by 85
Ripoll, M., Bernard, M., Vaure, C., Bazin, E., Commandeur, S., Perkov, V., Lemdani, K., Nicolaï, M., Bonifassi, P., Kichler, A., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121570 · Cited by 89
Label-free analysis of mRNA capping efficiency using RNase H probes and LC-MS
Beverly, M., Dell, A., Parmar, P., & Houghton, L. (2016) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-016-9605-x · Cited by 83
Huysmans, H., Zhong, Z., De Temmerman, J., Mui, B. L., Tam, Y. K., Mc Cafferty, S., Gitsels, A., Vanrompay, D., & Sanders, N. N. (2019) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2019.08.001 · Cited by 83
Tanaka, H., Nakatani, T., Furihata, T., Tange, K., Nakai, Y., Yoshioka, H., Harashima, H., & Akita, H. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b01084 · Cited by 82
Khorsand, B., Elangovan, S., Hong, L., Dewerth, A., Kormann, M., & Salem, A. K. (2017) · The AAPS Journal · doi:10.1208/s12248-016-0034-8 · Cited by 82
Self-citationChemically modified hCFTR mRNAs recuperate lung function in a mouse model of cystic fibrosis
Haque, A. K. M. A., Dewerth, A., Antony, J. S., Riethmüller, J., Schweizer, G. R., Weinmann, P., Latifi, N., Yasar, H., Pedemonte, N., Sondo, E., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-34960-0 · Cited by 80
Self-citationTranscript-activated collagen matrix as sustained mRNA delivery system for bone regeneration
Badieyan, Z. S., Berezhanskyy, T., Utzinger, M., Aneja, M. K., Emrich, D., Erben, R. G., Schüler, C., Altpeter, P., Ferizi, M., Hasenpusch, G., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.08.037 · Cited by 80
Self-citationJiang, T., Yu, N., Kim, J., Murgo, J.-R., Kissai, M., Ravichandran, K. R., Miracco, E. J., Presnyak, V., & Hua, S. S. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.9b01664 · Cited by 82
Lu, X., Xu, G., Lin, Z., Zou, F., Liu, S., Zhang, Y., Fu, W. E., Jiang, J., Ma, X., & Song, J. G. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00339-0 · Cited by 80
Steinle, H., Behring, A., Schlensak, C., Wendel, H. P., & Avci‐Adali, M. (2016) · Stem Cells · doi:10.1002/stem.2402 · Cited by 78
Kirschman, J. L., Bhosle, S. M., Vanover, D. A., Blanchard, E. L., Loomis, K. H., Zurla, C., Murray, K. A., Lam, B. C., & Santangelo, P. J. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx290 · Cited by 77
Maximizing the Translational Yield of mRNA Therapeutics by Minimizing 5′-UTRs
Trepotec, Z., Aneja, M. K., Geiger, J., Hasenpusch, G., Plank, C., & Rudolph, C. (2019) · Tissue Engineering Part A · doi:10.1089/ten.tea.2017.0485 · Cited by 77
Self-citationViral and Synthetic RNA Vector Technologies and Applications
Schott, J. W., Morgan, M., Galla, M., & Schambach, A. (2016) · Molecular Therapy · doi:10.1038/mt.2016.143 · Cited by 76
Self-Amplifying RNA Approach for Protein Replacement Therapy
Papukashvili, D., Rcheulishvili, N., Liu, C., Ji, Y., He, Y., & Wang, P. G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112884 · Cited by 76
Advances in Nanoparticles for Effective Delivery of RNA Therapeutics
Byun, M. J., Lim, J., Kim, S.-N., Park, D.-H., Kim, T. P., Park, W., & Park, C. G. (2022) · BioChip Journal · doi:10.1007/s13206-022-00052-5 · Cited by 78
Potential Therapeutic Applications of Rna Cap Analogs
Ziemniak, M., Strenkowska, M., Kowalska, J., & Jemielity, J. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.96 · Cited by 76
mRNA – A game changer in regenerative medicine, cell-based therapy and reprogramming strategies
Chabanovska, O., Galow, A.-M., David, R., & Lemcke, H. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114002 · Cited by 81
Moradian, H., Roch, T., Anthofer, L., Lendlein, A., & Gossen, M. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.01.004 · Cited by 77
Targeted lipid nanoparticles for RNA therapeutics and immunomodulation in leukocytes
Veiga, N., Diesendruck, Y., & Peer, D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.04.002 · Cited by 78
Vallazza, B., Petri, S., Poleganov, M. A., Eberle, F., Kuhn, A. N., & Şahin, U. (2015) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1288 · Cited by 74
Holstein, M., Mesa-Núñez, C., Miskey, C., Almarza, E., Poletti, V., Schmeer, M., Grueso, E., Flores, J. C. O., Kobelt, D., Walther, W., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.01.012 · Cited by 76
Self-citationTreating Cystic Fibrosis with mRNA and CRISPR
Sanchez, A. D. S., Paunovska, K., Cristian, A., & Dahlman, J. E. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.137 · Cited by 75
Recent advances in co-delivery nanosystems for synergistic action in cancer treatment
de Carvalho, B. G., Vit, F. F., Carvalho, H. F., Han, S. W., & de la Torre, L. G. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb02168g · Cited by 74
mRNA-based therapeutics–Advances and perspectives
Sergeeva, O. V., Koteliansky, V., & Zatsepin, T. S. (2016) · Biochemistry (Moscow) · doi:10.1134/s0006297916070075 · Cited by 74
A “top-down” approach to actuate poly(amine-co-ester) terpolymers for potent and safe mRNA delivery
Jiang, Y., Gaudin, A., Zhang, J., Agarwal, T., Song, E., Kauffman, A. C., Tietjen, G. T., Wang, Y., Jiang, Z., Cheng, C. J., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.05.043 · Cited by 72
mRNA Therapeutic Modalities Design, Formulation and Manufacturing under Pharma 4.0 Principles
Ouranidis, A., Vavilis, T., Mandala, E., Davidopoulou, C., Stamoula, Ε., Markopoulou, C. K., Karagianni, A., & Kachrimanis, K. (2021) · Biomedicines · doi:10.3390/biomedicines10010050 · Cited by 75
Yu, F., Witman, N., Yan, D., Zhang, S., Zhou, M., Yan, Y., Yao, Q., Ding, F., Yan, B., Wang, H., et al. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-02008-8 · Cited by 70
Do Cell-Penetrating Peptides Actually “Penetrate” Cellular Membranes?
Palm‐Apergi, C., Lönn, P., & Dowdy, S. F. (2012) · Molecular Therapy · doi:10.1038/mt.2012.40 · Cited by 73
Moyo, B., Bloom, K. M., Scott, T. A., Ely, A., & Arbuthnot, P. B. (2017) · Virus Research · doi:10.1016/j.virusres.2017.01.003 · Cited by 70
Schrom, E., Huber, M., Aneja, M., Dohmen, C., Emrich, D., Geiger, J., Hasenpusch, G., Herrmann-Janson, A., Kretzschmann, V., Mykhailyk, O., et al. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.04.006 · Cited by 69
Self-citationN1-methylpseudouridine found within COVID-19 mRNA vaccines produces faithful protein products
Kim, K. Q., Burgute, B. D., Tzeng, S., Jing, C., Jungers, C. F., Zhang, J., Yan, L. L., Vierstra, R. D., Djuranović, S., Evans, B. S., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111300 · Cited by 69
Nonviral Gene Therapy for Cancer: A Review
Hidai, C., & Kitano, H. (2018) · Diseases · doi:10.3390/diseases6030057 · Cited by 72
Chen, S., Zaifman, J., Kulkarni, J. A., Zhigaltsev, I. V., Tam, Y. K., Ciufolini, M. A., Tam, Y. Y. C., & Cullis, P. R. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.07.026 · Cited by 68
Xu, W., Zhang, S., Qin, H., & Yao, K. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05957-3 · Cited by 74
Bangel‐Ruland, N., Tomczak, K., Fernández, E. F., Leier, G., Leciejewski, B., Rudolph, C., Rosenecker, J., & Weber, W. (2013) · The Journal of Gene Medicine · doi:10.1002/jgm.2748 · Cited by 67
Self-citationSerum Nuclease Susceptibility of mRNA Cargo in Condensed Polyplexes
Yen, A., Cheng, Y., Sylvestre, M., Gustafson, H. H., Puri, S., & Pun, S. H. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00134 · Cited by 69
Uludağ, H., Ubeda, A., & Ansari, A. S. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00131 · Cited by 67
Huang, C., Leblond, A., Turner, E. C., Kumar, A. H. S., Martin, K., Whelan, D., O’Sullivan, D. M., & Caplice, N. M. (2015) · Molecular Pharmaceutics · doi:10.1021/mp5006239 · Cited by 70
Development of an mRNA replacement therapy for phenylketonuria
Pérez‐García, C. G., Dı́az-Trelles, R., Vega, J. B., Bao, Y., Sablad, M., Limphong, P., Chikamatsu, S., Yu, H., Taylor, W., Karmali, P. P., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.02.020 · Cited by 65
RNA-Based Tools for Nuclear Reprogramming and Lineage-Conversion: Towards Clinical Applications
Bernal, J. A. (2013) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-013-9494-8 · Cited by 65
Self-Replicating RNA Viruses for RNA Therapeutics
Lundstrom, K. H. (2018) · Molecules · doi:10.3390/molecules23123310 · Cited by 66
Chien, K. R., Zangi, L., & Lui, K. O. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014035 · Cited by 64
mRNA-Based Therapeutics in Cancer Treatment
Sun, H., Zhang, Y., Wang, G., Yang, W., & Xu, Y. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020622 · Cited by 65
Ongoing Clinical Trials of Nonviral siRNA Therapeutics
Narasipura, E. A., VanKeulen‐Miller, R., Ma, Y., & Fenton, O. S. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00205 · Cited by 66
Bérouti, M., Wagner, M., Greulich, W., Piseddu, I., Gärtig, J., Hansbauer, L., Müller-Hermes, C., Heiß, M., Pichler, A., Tölke, A. J., et al. (2025) · Cell · doi:10.1016/j.cell.2025.05.032 · Cited by 66
Aksoy, Y. A., Yang, B., Chen, W., Hung, T., Kuchel, R. P., Zammit, N. W., Grey, S. T., Goldys, E. M., & Deng, W. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c16380 · Cited by 63
Neutrophils Express Distinct RNA Receptors in a Non-canonical Way
Berger, M., Hsieh, C.-Y., Bakele, M., Marcos, V., Rieber, N. P., Kormann, M., Mays, L., Hofer, L., Neth, O., Vitkov, L., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.353557 · Cited by 62
Self-citationBalmayor, E. R., Geiger, J. P., Koch, C., Aneja, M. K., van Griensven, M., Rudolph, C., & Plank, C. (2016) · Stem Cells and Development · doi:10.1089/scd.2016.0171 · Cited by 62
Self-citationAn Improved, Chemically Modified RNA Encoding BMP-2 Enhances Osteogenesis In Vitro and In Vivo
Zhang, W., la Vega, R. E. D., Coenen, M. J., Müller, S., Silva, C. J. P., Aneja, M. K., Plank, C., van Griensven, M., Evans, C. H., & Balmayor, E. R. (2018) · Tissue Engineering Part A · doi:10.1089/ten.tea.2018.0112 · Cited by 62
Self-citationEnabling mRNA Therapeutics: Current Landscape and Challenges in Manufacturing
Youssef, M., Hitti, C., Fulber, J. P. C., & Kamen, A. (2023) · Biomolecules · doi:10.3390/biom13101497 · Cited by 63
mRNA therapies: Pioneering a new era in rare genetic disease treatment
Shen, G., Liu, J., Yang, H., Xie, N., & Yang, Y. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.03.056 · Cited by 62
Ren, Y., Lin, L., Abdallah, M., Zhu, X., Liu, H., Fabb, S. A., Payne, T. J., Pouton, C. W., Johnston, A. P. R., & Trevaskis, N. L. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113945 · Cited by 64
Non-viral therapeutic cell engineering with the Sleeping Beauty transposon system
Hudecek, M., & Ivics, Z. (2018) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2018.06.003 · Cited by 63
Therapeutic mRNA delivery to leukocytes
Granot-Matok, Y., Kon, E., Dammes, N., Mechtinger, G., & Peer, D. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.05.032 · Cited by 64
Recent Advances in the Noninvasive Delivery of mRNA
Qin, M., Du, G., & Sun, X. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00493 · Cited by 62
Targeting nucleic acid-based therapeutics to tumors: Challenges and strategies for polyplexes
Vetter, V. C., & Wagner, E. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.04.013 · Cited by 61
Yoshinaga, N., Uchida, S., Naito, M., Osada, K., Cabral, H., & Kataoka, K. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.01.023 · Cited by 59
Vascular Repair by Circumferential Cell Therapy Using Magnetic Nanoparticles and Tailored Magnets
Vosen, S., Rieck, S., Heidsieck, A., Mykhaylyk, O. M., Zimmermann, K., Bloch, W., Eberbeck, D., Plank, C., Gleich, B., Pfeifer, A., et al. (2016) · ACS Nano · doi:10.1021/acsnano.5b04996 · Cited by 58
Design, Assembly, Production, and Transfection of Synthetic Modified mRNA
Oh, S., & Kessler, J. A. (2018) · Methods · doi:10.1016/j.ymeth.2017.10.008 · Cited by 58
CRISPR-Cas9: a promising tool for gene editing on induced pluripotent stem cells
Kim, E. J., Kang, K. H., & Ju, J. H. (2017) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2016.198 · Cited by 58
Lipid-Nucleic Acid Complexes: Physicochemical Aspects and Prospects for Cancer Treatment
Gaspar, R., Coelho, F., & Silva, B. F. B. (2020) · Molecules · doi:10.3390/molecules25215006 · Cited by 59
Branched hydrophobic tails in lipid nanoparticles enhance mRNA delivery for cancer immunotherapy
Yan, Y., Liu, X., Wang, L., Wu, C., Shuai, Q., Zhang, Y., & Liu, S. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122279 · Cited by 56
Li, X., Li, J., Wei, J., Du, W., Su, C., Shen, X., Zhao, A., & Xu, M. (2025) · MedComm · doi:10.1002/mco2.70414 · Cited by 60
RNA therapeutics: Identification of novel targets leading to drug discovery
Qadir, M. I., Bukhat, S., Rasul, S., Manzoor, H., & Manzoor, M. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29364 · Cited by 57
Tanaka, H., Sakurai, Y., Anindita, J., & Akita, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.001 · Cited by 56
Optimization of Lipid Nanoformulations for Effective mRNA Delivery
Chen, H., Ren, X., Shi, X., Zhang, D., & Han, T. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s363990 · Cited by 55
Polyamine‐Mediated Stoichiometric Assembly of Ribonucleoproteins for Enhanced mRNA Delivery
Li, J., He, Y., Wang, W., Wu, C., Hong, C., & Hammond, P. T. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201707466 · Cited by 55
Self-amplifying mRNA vaccines: Mode of action, design, development and optimization
Pourseif, M. M., Masoudi‐Sobhanzadeh, Y., Azari, E., Parvizpour, S., Barar, J., Ansari, R. A., & Omidi, Y. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103341 · Cited by 57
Andries, O., Filette, M. D., Smedt, S. C. D., Demeester, J., Poucke, M. V., Peelman, L. J., & Sanders, N. N. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.01.033 · Cited by 54
Genetic medicines for CF: Hype versus reality
Alton, E. W. F. W., Boyd, A. C., Davies, J. C., Gill, D. R., Griesenbach, U., Harrison, P. T., Henig, N., Higgins, T., Hyde, S. C., Innes, J. A., et al. (2016) · Pediatric Pulmonology · doi:10.1002/ppul.23543 · Cited by 53
Murthy, N., Lee, K., Yu, P., Lingampalli, N., Kim, H. J., & Tang, R. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s75124 · Cited by 53
Lescan, M., Perl, R. M., Golombek, S., Pilz, M., Hann, L., Yasmin, M., Behring, A., Keller, T., Nolte, A., Gruhn, F., et al. (2018) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2018.03.013 · Cited by 52
Engineering therapeutic protein disaggregases
Shorter, J. (2016) · Molecular Biology of the Cell · doi:10.1091/mbc.e15-10-0693 · Cited by 53
Synthetic long non-coding RNAs [SINEUPs] rescue defective gene expression in vivo
Indrieri, A., Grimaldi, C., Zucchelli, S., Tammaro, R., Gustincich, S., & Franco, B. (2016) · Scientific Reports · doi:10.1038/srep27315 · Cited by 52
Therapeutic mRNA Engineering from Head to Tail
Jia, L., & Qian, S. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00541 · Cited by 51
Yeom, J., Ryou, S.-M., Won, M., Park, M., Bae, J., & Lee, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075369 · Cited by 51
Avci‐Adali, M., Behring, A., Keller, T., Krajewski, S., Schlensak, C., & Wendel, H. P. (2014) · Journal of Biological Engineering · doi:10.1186/1754-1611-8-8 · Cited by 55
Chin, R. M., Panavas, T., Brown, J. M., & Johnson, K. K. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.02.059 · Cited by 50
The Dual Role of the Innate Immune System in the Effectiveness of mRNA Therapeutics
Muslimov, A. R., Tereshchenko, V., Shevyrev, D., Rogova, A. S., Lepik, K. V., Reshetnikov, V. V., & Ivanov, R. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914820 · Cited by 51
Advances in the design and delivery of RNA vaccines for infectious diseases
Lokras, A. G., Bobak, T. R., Baghel, S. S., Sebastiani, F., & Foged, C. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115419 · Cited by 52
Synthetic biology devices and circuits for RNA-based ‘smart vaccines’: a propositional review
Andries, O., Kitada, T., Bodner, K., Sanders, N. N., & Weiss, R. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.997714 · Cited by 50
Metadata
- Authors
- Kormann, M. S. D., Hasenpusch, G., Aneja, M. K., Nica, G., Flemmer, A. W., Herber-Jonat, S., Huppmann, M., Mays, L. E., Illenyi, M., Schams, A., Griese, M., Bittmann, I., Handgretinger, R., Hartl, D., Rosenecker, J., & Rudolph, C.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- University Children's Hospital Tübingen (DE)
- Agaplesion Diakonieklinikum Rotenburg (DE)
- Corresponding author
- Kormann, Michael S D
- Rudolph, Carsten
- ORCID
- Venue
- Nature Biotechnology
- Published
- 2011-01-09
- Volume
- 29
- Issue
- 2
- Pages
- 154-157
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2071302752
- Cited by
- 733
- References
- 27
- Citations by year
- 2026: 26 · 2025: 41 · 2024: 59 · 2023: 54 · 2022: 64 · 2021: 61 · 2020: 69 · 2019: 53 · 2018: 56 · 2017: 58 · 2016: 65 · 2015: 48 · 2014: 23 · 2013: 28 · 2012: 17
- FWCI
- 10.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
- Keywords
- chemically modified mRNA, mRNA therapeutics, erythropoietin, surfactant protein B, immunogenicity, Toll-like receptors, RIG-I, intramuscular injection, hematocrit, non-viral gene therapy, lung disease
- MeSH terms
- Animals, Erythropoietin, Histocytochemistry, Lung, Mice, Transgenic, Proteolipids, RNA, Messenger, Gene Transfer Techniques, RNA Stability, Mice, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
